Skip to main content
SpringerLink
Log in

In vivo anti-inflammatory effects of the M20 IL-1 Inhibitor: II. Effects on serum reactants

  • Research Articles
  • Published:
Biotherapy

Abstract

We have previously described an IL-1 Inhibitor derived from the M20 myelomoncytic cell line. This line also secretes several molecules of IL-1. We have shown that this factor is specific to IL-1in vitro, as well asin vivo. In vitro IL-1 induced proliferative responses of mouse thymocytes, human T cells and fibroblasts and IL-1 stimulated PGE2 secretion from fibroblasts, were all inhibited by the M20 IL-1 Inhibitor.In vivo, the IL-1 Inhibitor reduced parameters of acute inflammation such as fever, leukocytosis and local inflammation. This study describes additional effects of the M20 IL-1 Inhibitor on inflammatory serum reactants. Levels of corticosterone and fibrinogen were increased by injection of IL-1, and decreased by the IL-1 Inhibitor. IL-1 reduced zinc and iron plasma levels and elevated copper plasma levels. The M20 IL-1 Inhibitor reversed these changes in a dose dependent manner. Similar effects produced by IL-6 and TNF were unaffected by the M20 IL-1 Inhibitor. Our results indicate that the M20 IL-1 Inhibitor acts specifically on IL-1 induced responsesin vivo. Therefore we conclude that this IL-1 Inhibitor has a great potential as an anti-inflammatory agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

IL-1:

Interleukin 1

IL-6:

Interleukin 6

IL-1ra:

Interleukin 1 receptor antagonist

TNF:

tumor necrosis factor

References

  1. Dinarello CA. Interleukin-1 and its biologically related cytokines. Adv Immunol 1989; 44: 153–205.

    PubMed  Google Scholar 

  2. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627–1652.

    PubMed  Google Scholar 

  3. Dinarello CA. Anti-cytokine strategies. Eur Cytokine Netw 1992: 3: 7–17.

    PubMed  Google Scholar 

  4. Larrick JW. Native interleukin-1 inhibitors. Immunol Today 1989; 10: 61–66.

    PubMed  Google Scholar 

  5. Dayer JM, Seckinger P. Natural inhibitors and antagonists of interleukin-1, In: Bomford RHR, Henderson B, eds. Interleukin-1, Inflammation and Disease. Amsterdam: Elsevier, 1989.

    Google Scholar 

  6. Brown K, Muchmore AV, Rosenstreich, DL. Uromodulin, an immunosuppressive protein derived from pregnancy urine, is an inhibitor of IL-1. Proc. Natl Acad Sci, USA 1987 83: 9119–9123.

    Google Scholar 

  7. Hannum C, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL, Armes LG, Sommer A, Eisenberg SP, Thompson RC. IL-1 receptor antagonist activity of a human IL-1 Inhibitor. Nature 1990; 343: 336–340.

    PubMed  Google Scholar 

  8. Matsushima K, Yodai J, Tagaya Y, Oppenheim JJ. Down regulation of ihterleukin-1 receptor expression by IL-1 and fate of internalized 125-I labeled IL-1β in a human large granular lymphocyte cell line. J Immunol 1986; 137: 3183–3188.

    PubMed  Google Scholar 

  9. Mizel SB. Cyclic AMP and interleukin-1 signal transduction. Immunol Today 1990; 11: 390–391.

    PubMed  Google Scholar 

  10. Mazzei GJ, Seckinger PL, Dayer, JM, Shaw, AR. Purification and characterization of a 26 kDa competitive inhibitor of interleukin-1. Eur J Immunol 1990; 20: 683–689.

    PubMed  Google Scholar 

  11. Eisenberg SP, Evans RJ, Arend WP, Verderber E, Brewer MT, Hannum CH, Thompson RC. Primary structure and functional expression from complementary DNA of a human IL-1 receptor antagonist. Nature 1990; 343: 341–346.

    PubMed  Google Scholar 

  12. Arrend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte derived interleukin-1 receptor antagonist. J Clin Invest 1990; 85: 1694–1697.

    PubMed  Google Scholar 

  13. Carter DB, Deibel MRJ, Dunn CJ, Tomich CS, Laborde AL, Slightom JL, Berger AE, Bienkowski MJ, Sun FF, McEwan RN, Harris PKW, Yem AW, Waszak GA, Chosay JG, Sieu LC, Hardee MM, Zurcher-Neeley HA, Reardon IM, Heinrickson RL, Truesdall SE, Sheely JA, Eessalu TE, Taylor BM, Tracey DE. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein (IRAP). Nature 1990; 344: 633–638.

    PubMed  Google Scholar 

  14. Haskill S, Martin M, VanLe L, Morris J, Peace A, Bigler CF, Jaffe GJ, Sporn SA, Fong S, Arend WP, Ralph P. cDNA cloning of a novel form of the interleukin-1 receptor antagonist associated with epithelium. Proc Natl Acad Sci, USA 1991; 88: 3681–3685.

    Google Scholar 

  15. Barak V, Treves AJ, Yanai P, Halperin M, Biran S, Braun S. Interleukin-1 inhibitory activity secreted by a human myelomonocytic cell line (M20). Eur J Immunol 1986; 16: 1449–1452.

    PubMed  Google Scholar 

  16. Treves AJ, Halperin M, Barak V, Bar Tana R, Halimi B, Fibach E, Gamliel H, Leizerowitz R, Polliack A. A new myelomonocytic cell line: Analysis of properties, differentiation and comparison with other established lines of similar origin. Exp Hemat 1985; 13: 281–288.

    PubMed  Google Scholar 

  17. Barak V, Yamin M, Braun S, Halperin M., Biran S., Milner Y, Treves AJ. Detection of different IL-1 activities in human monocytes and monocytic lines. J Biol Resp Mod 1986; 5: 362–375.

    Google Scholar 

  18. Peritt D, Flechner I., Okunev E, Yanai P, Halperin T, Treves AJ, Barak V. The M20 IL-1 Inhibitor: I: Purification by preparative isoelectric focusing in free solution. J Immunol Methods 1992; 155: 159–165.

    Google Scholar 

  19. Peritt D, Flechner I, Yanai P, Okunev E, Halperin T, Treves AJ, Barak V. The M20 IL-1 Inhibitor: II: Biological characterization. J Immunol Methods 1992; 155: 167–174.

    Google Scholar 

  20. Barak V, Peritt D, Flechner I, Yanai P, Halperin T, Treves AJ, Dinarello CA. The specific IL-1 inhibitor from the human M20 cell line is distinct from the IL-1 receptor antagonist. Lymphokine and Cytokine Research 1991, 10: 437–442.

    PubMed  Google Scholar 

  21. Barak V, Treves AJ. Interleukin-1 inhibitor: Characterization of mechanism of activity. Lymphokine Research 1988; 7: 268.

    Google Scholar 

  22. Barak V, Peritt D, Yanai P, Flechner I, Halperin T, Okon E, Sherman Y, Treves AJ. The M20 IL-1 Inhibitor prevents onset and reduces rheumatoid arthritis in a rat model. Biotherapy 1992; 4: 317–323.

    PubMed  Google Scholar 

  23. Barak V, Peritt D, Yanai P, Halperin T, Treves A J.In vivo anti inflamatory effects of the M20 IL-1 Inhibitor. I. Effects on acute inflammatory parameters. (Part I of this paper.)

  24. Klasing KE. Effect of inflammatory agents and interleukin 1 on iron and zinc metabolism. Am J Physiol 1984; 247: R901-R904.

    PubMed  Google Scholar 

  25. Goldblum SE, Cohen DA, Jay H, McClain, C. Interleukin 1 induced depression of iron and zinc: role of granulocytes and lactoferrin. Am J Physiol 1987; 252: E27-E32.

    PubMed  Google Scholar 

  26. Smith BJ, Speziale SC, Bowman BJ. Properties of interleukin-1 as a complete secretagogue for human neutrophils. Biochem Biophys Res Commun 1985; 130: 1233–1240.

    PubMed  Google Scholar 

  27. Besedovsky H, Del Rey A, Sorkin E, Dinarello CA. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 1986; 233: 652–654.

    PubMed  Google Scholar 

  28. Ovadia H, Abramsky O, Barak V, Conforti N, Saphier D, Weidenfeld J. Neural differentiation of the hypothalamus abolishes the effect of interleukin 1 on adrenocortical activity. Exp Brain Res 1989; 76: 246–249.

    PubMed  Google Scholar 

  29. Morrissey PJ, Charrier K, Alpert A, Bressler L. In vivo administration of IL-1 induces thymic hypoplasia and increased levels of serum corticosterone. J Immunol 1988; 141: 1456–1463.

    PubMed  Google Scholar 

  30. Peled T, Rigel M, Peritt D, Treves AJ, Fibach E, Barak V. The effect of the M20 IL-1 inhibitor on proliferation and differentiation of leukemic cells. Blood 1992; 79: 1172–1177.

    PubMed  Google Scholar 

  31. Dinarello CA, Thompson RC. Blocking IL-1: Interleukin 1 receptor antagonistin vivo andin vitro. Immunol Today 1991; 12: 404–410.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Immunology Laboratory, Oncology Department, Hadassah University Hospital, Jerusalem, Israel

    Vivian Barak, Raphael Gorodetsky, Josef Weidenfeld, David Peritt, Peter Yanai, Tal Halperin & Abraham J. Treves

Authors
  1. Vivian Barak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raphael Gorodetsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Josef Weidenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Peritt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter Yanai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tal Halperin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Abraham J. Treves
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barak, V., Gorodetsky, R., Weidenfeld, J. et al. In vivo anti-inflammatory effects of the M20 IL-1 Inhibitor: II. Effects on serum reactants. Biotherapy 6, 271–277 (1993). https://doi.org/10.1007/BF01878356

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01878356

Key words

Search

Navigation